Although the FDA has rejected Stealth’s new drug application for Barth syndrome candidate elamipretide, the agency identified ...

Analysts at Truist Securities admitted that the result for itepekimab, which the companies were hoping to follow their ...

Despite mixed results, analysts maintained faith in ivonescimab’s ability to cross over between Eastern and Western patient ...

The National Legal and Policy Center, a right-wing advocacy and watchdog group, had asked the company to revisit its DEI ...

At the heart of the deal is an anti-Claudin18.2 antibody-drug conjugate being developed for solid tumors, including gastric ...

Keros will be down to 85 full-time employees after the layoffs and expects to generate annualized savings of $17 million.

According to the nonprofit news outlet NOTUS, at least seven studies cited in the Make America Healthy Again report released ...

While an adverse event reported in Intellia’s gene therapy trial was a “non-concern” for analysts, it follows a handful of ...

Patritumab deruxtecan was unable to significantly improve overall survival in patients with locally advanced or metastatic ...

Looking for a biopharma job in New York? Check out the BioSpace list of seven companies hiring life sciences professionals ...

Teos expects to absorb nearly $25 million in one-time costs for severance and termination payments. The biotech had 173 ...

The canceled contract comes as Moderna nears a critical FDA decision for its next-generation COVID-19 vaccine.